预防性HIV疫苗试验中末次接种后六个月持久免疫应答的预测因素
该研究纳入三项临床试验中七种预防性HIV疫苗方案的201名受种者,用正则化随机森林和线性回归分析基线人口学变量及接种后两周免疫应答对六个月持久应答的预测作用。结果显示,同一生物标志物两周应答水平对持久应答阳性预测接近完美、对幅度预测相关系数最高达0.91,加入人口学信息和其他标志物两周水平改善甚微。
要点
- 同一生物标志物接种后两周应答水平可较好预测六个月持久应答。
- 持久应答阳性预测接近完美,幅度预测相关系数最高达0.91。
- 加入人口学信息和其他标志物两周水平对预测改善甚微。
核心结论
- 对部分生物标志物和所研究的疫苗,接种后两周应答可较好预测六个月后的持久应答。
- 若仅在受种者子样本中评估免疫应答持久性,纳入两周应答数据可提高持久应答统计分析的效率。
- 需进一步研究以将结果推广至其他疫苗方案和生物标志物。
研究设计与样本
- 研究纳入三项临床试验中评估的七种预防性HIV疫苗方案数据:HVTN096为四种DNA、NYVAC和/或AIDSVAX疫苗方案的1期研究,HVTN205为两种DNA和/或MVA疫苗方案的2期研究,RV144为单一ALVAC/AIDSVAX方案的3期研究。
- 分析201名疫苗受种者,数据包括10至127个免疫应答生物标志物和3至5个人口学变量。
- 采用正则化随机森林和线性回归模型识别和评估持久免疫应答阳性及幅度的预测因素。
主要发现
- 基于两周应答对受种者持久应答阳性的最佳预测接近完美准确。
- 基于两周应答对受种者持久应答幅度的最佳预测,观察值与预测值之间的相关系数最高达0.91。
- 不同生物标志物间预测性能存在差异,但持久免疫应答最好由同一生物标志物的两周应答水平预测。
- 加入人口学信息和其他生物标志物的两周应答水平对预测改善甚微或无改善。
局限性
- 需进一步研究以将结果推广至其他疫苗方案和生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The evaluation of durable immune responses is important in HIV vaccine research and development. The efficiency of such evaluation could be increased by incorporating predictors of the responses in the statistical analysis. In this paper, we investigated whether and how baseline demographic variables and immune responses measured two weeks after vaccination predicted durable immune responses measured six months later. METHODS: We included data from seven preventive HIV vaccine regimens evaluated in three clinical trials: a Phase 1 study of four DNA, NYVAC and/or AIDSVAX vaccine regimens (HVTN096), a Phase 2 study of two DNA and/or MVA vaccine regimens (HVTN205), and a Phase 3 study of a single ALVAC/AIDSVAX regimen (RV144). Regularized random forests and linear regression models were used to identify and evaluate predictors of the positivity and magnitude of durable immune responses. RESULTS: We analyzed 201 vaccine recipients with data from 10 to 127 immune response biomarkers, and 3-5 demographic variables. The best prediction of participants' durable response positivity based on two-week responses rendered up to close-to-perfect accuracy; the best prediction of participants' durable response magnitude rendered correlation coefficients between the observed and predicted responses ranging up to 0.91. Though prediction performances differed among biomarkers, durable immune responses were best predicted by the two-week response level of the same biomarker. Adding demographic information and two-week response levels of different biomarkers provided little or no improvement in the predictions. CONCLUSIONS: For some biomarkers and for the vaccines we studied, two-week post-vaccination responses can well predict durable responses six months later. Therefore, if immune response durability is only assessed in a sub-sample of vaccine recipients, statistical analyses of durable responses will have increased efficiency by incorporating two-week response data. Further research is needed to generalize the findings to other vaccine regimens and biomarkers. Clinicaltrials.gov identifiers: NCT01799954, NCT00820846, NCT00223080.
引用
- Huang Y, Zhang L, Janes H, et al. Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials. Vaccine. 2017. PMID: 28131393. doi:10.1016/j.vaccine.2016.09.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。